Your browser doesn't support javascript.
loading
In Situ Aggregated Nanomanganese Enhances Radiation-Induced Antitumor Immunity.
Xu, Jialong; Wang, Chao; Zhang, Li; Zhao, Chuan; Zhao, Xiaozhi; Wu, Jinhui.
Afiliação
  • Xu J; Medical School of Nanjing University, Nanjing 210093, China.
  • Wang C; Medical School of Nanjing University, Nanjing 210093, China.
  • Zhang L; Jiangsu Agri-Animal Husbandry Vocational College, Taizhou 225300, China.
  • Zhao C; Medical School of Nanjing University, Nanjing 210093, China.
  • Zhao X; Department of Andrology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing 210023, China.
  • Wu J; Medical School of Nanjing University, Nanjing 210093, China.
ACS Appl Mater Interfaces ; 16(27): 34450-34466, 2024 Jul 10.
Article em En | MEDLINE | ID: mdl-38941284
ABSTRACT
Radiosensitizers play a pivotal role in enhancing radiotherapy (RT). One of the challenges in RT is the limited accumulation of nanoradiosensitizers and the difficulty in activating antitumor immunity. Herein, a smart strategy was used to achieve in situ aggregation of nanomanganese adjuvants (MnAuNP-C&B) to enhance RT-induced antitumor immunity. The aggregated MnAuNP-C&B system overcomes the shortcomings of small-sized nanoparticles that easily flow back into blood vessels and diffuse into surrounding tissues, and it also prolongs the retention time of nanomanganese within cancer cells and tumors. The MnAuNP-C&B system significantly enhances the radiosensitization effect in RT. Additionally, the pH-responsive disassembly of MnAuNP-C&B triggers the release of Mn2+, further promoting RT-induced activation of the STING pathway and eliciting robust antitumor immunity. Overall, our study presents a smart strategy wherein in situ aggregation of nanomanganese effectively inhibits tumor growth through radiosensitization and the activation of antitumor immunity.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Radiossensibilizantes Limite: Animals / Female / Humans Idioma: En Revista: ACS Appl Mater Interfaces Assunto da revista: BIOTECNOLOGIA / ENGENHARIA BIOMEDICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Radiossensibilizantes Limite: Animals / Female / Humans Idioma: En Revista: ACS Appl Mater Interfaces Assunto da revista: BIOTECNOLOGIA / ENGENHARIA BIOMEDICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China